patent/IN-2014MU00916-A

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5053f82a7cd17c60822674b657cfb89e
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536
filingDate	2015-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_606a5b25ade5d0dde71a6c04bb121b79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32ad655c1c4699081708494ba10385c1
publicationDate	2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	IN-2014MU00916-A
abstract	The present invention relates to a pharmaceutical composition comprising an integrase inhibitor, and more particularly, relates to a pharmaceutical composition comprising dolutegravir, a process for preparing such pharmaceutical composition, and its use in the treatment of HIV infections.
priorityDate	2014-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419510094 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54726191

Total number of triples: 17.